Stuttgart - Delayed Quote • EUR Capricor Therapeutics Inc (4LN2.SG) Follow Compare 14.24 +1.04 +(7.88%) At close: 9:34:14 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 4LN2.SG 1D 5D 6.59% 1M 9.37% 3M -27.79% 6M 429.17% YTD 9.37% 1Y 429.17% 5Y 429.17% All 72.19% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 4LN2.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy High Growth Tech Stocks To Watch In December 2024 Capricor Therapeutics to Present at Upcoming Investor Conferences Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations Q3 2024 Capricor Therapeutics Inc Earnings Call Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates Related Tickers 2LB.BE Iovance Biotherapeutics Inc 5.99 +0.67% 2LB.F Iovance Biotherapeutics, Inc. 5.99 +0.77% IFRX InflaRx N.V. 2.4100 +1.69% NVAX Novavax, Inc. 8.69 -3.55% MRNA Moderna, Inc. 39.42 -3.95%